In T-cell lymphoma patients, the DNMT3A mutation was detected in both T-lymphoma cells and the CD19+ blood fraction, whereas the TET2 mutation was shared between neoplastic clone, B cells and HSPCs (254, 255). This evidence concerns the gene CD19 and lymphoma.